rajasekharkakarla
☆    

India,
2019-09-20 08:35
(2470 d 03:18 ago)

Posting: # 20628
Views: 2,907
 

 Reference replicated designs [Regulatives / Guidelines]

Post reply
Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar
 
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
155 visitors (0 registered, 155 guests [including 23 identified bots]).
Forum time: 11:54 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5